Protocol for TRAUMADORNASE: a prospective, randomized, multicentre, double-blinded, placebo-controlled clinical trial of aerosolized dornase alfa to reduce the incidence of moderate-to-severe hypoxaemia in ventilated trauma patients

MLA

Julien Pottecher, et al. “Protocol for TRAUMADORNASE: A Prospective, Randomized, Multicentre, Double-Blinded, Placebo-Controlled Clinical Trial of Aerosolized Dornase Alfa to Reduce the Incidence of Moderate-to-Severe Hypoxaemia in Ventilated Trauma Patients.” Trials, vol. 21, no. 1, Mar. 2020, pp. 1–13. EBSCOhost, https://doi.org/10.1186/s13063-020-4141-6.

APA

Julien Pottecher, Eric Noll, Marie Borel, Gérard Audibert, Sébastien Gette, Christian Meyer, Elisabeth Gaertner, Vincent Legros, Raphaël Carapito, Béatrice Uring-Lambert, Erik Sauleau, Walter G. Land, Seiamak Bahram, Alain Meyer, Bernard Geny, & Pierre Diemunsch. (2020). Protocol for TRAUMADORNASE: a prospective, randomized, multicentre, double-blinded, placebo-controlled clinical trial of aerosolized dornase alfa to reduce the incidence of moderate-to-severe hypoxaemia in ventilated trauma patients. Trials, 21(1), 1–13. https://doi.org/10.1186/s13063-020-4141-6

Chicago

Julien Pottecher, Eric Noll, Marie Borel, Gérard Audibert, Sébastien Gette, Christian Meyer, Elisabeth Gaertner, et al. 2020. “Protocol for TRAUMADORNASE: A Prospective, Randomized, Multicentre, Double-Blinded, Placebo-Controlled Clinical Trial of Aerosolized Dornase Alfa to Reduce the Incidence of Moderate-to-Severe Hypoxaemia in Ventilated Trauma Patients.” Trials 21 (1): 1–13. doi:10.1186/s13063-020-4141-6.